A comparison of sacral neuromodulation vs. transvaginal electrical stimulation for the treatment of refractory overactive bladder: the impact on quality of life, body image, sexual function, and emotional well-being

Valentina Lucia La Rosa, Alessio Platania, Michał Ciebiera, Simone Garzon, Robert Jędra, Marco Ponta, Salvatore Butticè, Valentina Lucia La Rosa, Alessio Platania, Michał Ciebiera, Simone Garzon, Robert Jędra, Marco Ponta, Salvatore Butticè

Abstract

Overactive bladder syndrome (OAB) is defined by the presence of urinary urgency, with or without urge incontinence, usually accompanied by an increase in urinary frequency and nocturia in the absence of urinary tract infections (UTI) or other diseases. The overall prevalence of OAB symptoms in the female population is reported to be 16.6% and increases with advancing age and menopause. The aetiology of OAB is not fully understood and is likely to affect a heterogeneous population of patients due to changes to their central and peripheral nervous systems. Although OAB is frequently associated with female sexual dysfunction (FSD), its real impact on sexual function in women has been evaluated only in a few studies. The first line of treatment for OAB includes behavioural modification and physical therapy, either as monotherapies or in combination. Many patients who have not had success in managing their symptoms with more conservative therapies may decide to resort to third-line treatments for refractory OAB. These treatments include neuromodulation therapies, particularly transvaginal electrical stimulation (TES) and sacral neuromodulation (SN). The aim of this short commentary is to provide an overview of the effectiveness of these treatments and of their impact on quality of life, body image, sexual function, and emotional well-being.

Keywords: menopause; overactive bladder syndrome; quality of life; sacral neuromodulation; sexual function; transvaginal electrical stimulation.

Conflict of interest statement

The authors report no conflict of interest.

References

    1. Sultan AH, Monga A, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female anorectal dysfunction. Neurourol Urodyn. 2017;36:10–34.
    1. Abrams P, Andersson KE, Birder L, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29:213–240.
    1. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology. 2003;62:28–37. discussion 40-42.
    1. Patnaik SS, Laganà AS, Vitale SG, et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Arch Gynecol Obstet. 2017;295:1341–1359.
    1. Grundy L, Caldwell A, Brierley SM. Mechanisms Underlying Overactive Bladder and Interstitial Cystitis/Painful Bladder Syndrome. Front Neurosci. 2018;12:931.
    1. Laganà AS, La Rosa VL, Rapisarda AMC, et al. Pelvic organ prolapse: The impact on quality of life and psychological well-being. J Psychosom Obstet Gynecol. 2018;39:164–166.
    1. Kim MS, Lee GH, Na ED, et al. The association of pelvic organ prolapse severity and improvement in overactive bladder symptoms after surgery for pelvic organ prolapse. Obstet Gynecol Sci. 2016;59:214–219.
    1. Vercellini P, Bracco B, Mosconi P, et al. Norethindrone acetate or dienogest for the treatment of symptomatic endometriosis: a before and after study. Fertil Steril. 2016;105:734–743.e3.
    1. Vitale SG, La Rosa VL, Rapisarda AMC, et al. The Importance of a Multidisciplinary Approach or Women with Pelvic Organ Prolapse and Cystocele. Oman Med J. 2017;32:263–264.
    1. Digesu GA, Salvatore S, Chaliha C, et al. Do overactive bladder symptoms improve after repair of anterior vaginal wall prolapse? Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:1439–1443.
    1. Vitale SG, Laganà AS, Noventa M, et al. Transvaginal Bilateral Sacrospinous Fixation after Second Recurrence of Vaginal Vault Prolapse: Efficacy and Impact on Quality of Life and Sexuality. Biomed Res Int. 2018;2018:5727165.
    1. Clemons JL, Aguilar VC, Tillinghast TA, et al. Patient satisfaction and changes in prolapse and urinary symptoms in women who were fitted successfully with a pessary for pelvic organ prolapse. Am J Obstet Gynecol. 2004;190:1025–1029.
    1. Vitale SG, Laganà AS, Gulino FA, et al. Prosthetic surgery versus native tissue repair of cystocele: literature review. Updates Surg. 2016;68:325–329.
    1. Laganà AS, Sapia F, Butticè S, et al. Comment on “efficacy and safety of skeletonized mesh implants for advanced pelvic organ prolapse: 12 month follow up”. World J Urol. 2016;34:1499–1500.
    1. Vitale SG, Laganà AS, Rapisarda AMC. Letter to the editor: Comment on “Simultaneous treatment of anterior vaginal wall prolapse and stress urinary incontinence by using transobturator four arms polypropylene mesh”. Investig Clin Urol. 2016;57:150–151.
    1. Ko YH, Song C-H, Choi JW, et al. Effect on Sexual Function of Patients and Patients’ Spouses After Midurethral Sling Procedure for Stress Urinary Incontinence: A Prospective Single Center Study. Low Urin Tract Symptoms. 2016;8:182–185.
    1. Laganà AS, La Rosa VL, Rapisarda AMC, et al. Comment on: “Effect on Sexual Function of Patients and Patients’ Spouses After Midurethal Sling Procedure for Stress Urinary Incontinence: A Prospective Single Center Study”. Low Urin Tract Symptoms. 2017;9:62.
    1. Koch M, Rauchenwald T, Kivaranovic D, et al. Association of uterine leiomyoma and overactive bladder syndrome. Int J Gynaecol Obstet. 2018;142:365–369.
    1. Stewart EA, Cookson CL, Gandolfo RA, et al. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124:1501–1512.
    1. Laganà AS, Vergara D, Favilli A, et al. Epigenetic and genetic landscape of uterine leiomyomas: a current view over a common gynecological disease. Arch Gynecol Obstet. 2017;296:855–867.
    1. Vitale SG, Sapia F, Rapisarda AMC, et al. Hysteroscopic Morcellation of Submucous Myomas: A Systematic Review. Biomed Res Int. 2017;2017:6848250.
    1. Hazewinkel MH, Sprangers MAG, van der Velden J, et al. Long-term cervical cancer survivors suffer from pelvic floor symptoms: a cross-sectional matched cohort study. Gynecol Oncol. 2010;117:281–286.
    1. Axelsen SM, Bek KM, Petersen LK. Urodynamic and ultrasound characteristics of incontinence after radical hysterectomy. Neurourol Urodyn. 2007;26:794–799.
    1. Bellia A, Vitale SG, Laganà AS, et al. Feasibility and surgical outcomes of conventional and robot-assisted laparoscopy for early-stage ovarian cancer: a retrospective, multicenter analysis. Arch Gynecol Obstet. 2016;294:615–622.
    1. Rossetti D, Vitale SG, Gulino FA, et al. Concomitant chemoradiation treatment in selected Stage I endometrioid endometrial cancers. Eur J Gynaecol Oncol. 2016;37:657–661.
    1. Cignini P, Vitale SG, Laganà AS, et al. Preoperative work-up for definition of lymph node risk involvement in early stage endometrial cancer: 5-year follow-up. Updates Surg. 2017;69:75–82.
    1. Kruppa J, Kavvadias T, Amann S, et al. Short and long-term urodynamic and quality of life assessment after nerve sparing radical hysterectomy: a prospective pilot study. Eur J Obstet Gynecol Reprod Biol. 2016;201:131–134.
    1. Vitale SG, Capriglione S, Zito G, et al. Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition. Arch Gynecol Obstet. 2019;299:299–315.
    1. Bruno A, Laganà AS, Leonardi V, et al. Inside-out: the role of anger experience and expression in the development of postpartum mood disorders. J Matern Fetal Neonatal Med. 2018;31:3033–3038.
    1. Hullfish KL, Fenner DE, Sorser SA, et al. Postpartum depression, urge urinary incontinence, and overactive bladder syndrome: is there an association? Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:1121–1126.
    1. Melville JL, Walker E, Katon W, et al. Prevalence of comorbid psychiatric illness and its impact on symptom perception, quality of life, and functional status in women with urinary incontinence. Am J Obstet Gynecol. 2002;187:80–87.
    1. Tadic SD, Holstege G, Griffiths DJ. The CNS and bladder dysfunction. F1000 Med Rep. 2012;4:20.
    1. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–766.
    1. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64:2–6.
    1. Vitale SG, Caruso S, Rapisarda AMC, et al. Isoflavones, calcium, vitamin D and inulin improve quality of life, sexual function, body composition and metabolic parameters in menopausal women: Result from a prospective, randomized, placebo-controlled, parallel-group study. Prz Menopauzalny. 2018;17:32–38.
    1. Cianci A, Colacurci N, Paoletti AM, et al. Soy Isoflavones, Inulin, Calcium, and Vitamin D3 in post-menopausal hot flushes: An observational study. Clin Exp Obstet Gynecol. 2015;42:743–745.
    1. Chen Y, Yu W, Yang Y, et al. Association between overactive bladder and peri-menopause syndrome: a cross-sectional study of female physicians in China. Int Urol Nephrol. 2015;47:743–749.
    1. Zhu L, Cheng X, Sun J, et al. Association between Menopausal Symptoms and Overactive Bladder: A Cross-Sectional Questionnaire Survey in China. PLoS One. 2015;10:e0139599.
    1. Hakimi S, Aminian E, Alizadeh Charandabi SM, et al. Risk factors of overactive bladder syndrome and its relation to sexual function in menopausal women. Urologia. 2018;85:10–14.
    1. Roxburgh C, Cook J, Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2007:CD003190.
    1. Duthie JB, Vincent M, Herbison GP, et al. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011:CD005493.
    1. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–1395.
    1. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6:S580–590.
    1. Lee KS, Choo MS, Seo JT, et al. Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS) Health Qual Life Outcomes. 2015;13:89.
    1. Oh S-J, Ku JH, Choo M-S, et al. Health-related quality of life and sexual function in women with stress urinary incontinence and overactive bladder. Int J Urol. 2008;15:62–67. discussion 67.
    1. Coyne KS, Margolis MK, Jumadilova Z, et al. Overactive bladder and women’s sexual health: what is the impact? J Sex Med. 2007;4:656–666.
    1. Juliato CRT, Melotti IGR, Junior LCS, et al. Does the Severity of Overactive Bladder Symptoms Correlate With Risk for Female Sexual Dysfunction? J Sex Med. 2017;14:904–909.
    1. Berman JR, Adhikari SP, Goldstein I. Anatomy and physiology of female sexual function and dysfunction: classification, evaluation and treatment options. Eur Urol. 2000;38:20–29.
    1. Vitale SG, Caruso S, Rapisarda AMC, et al. Biocompatible porcine dermis graft to treat severe cystocele: impact on quality of life and sexuality. Arch Gynecol Obstet. 2016;293:125–131.
    1. Caruso S, Bandiera S, Cavallaro A, et al. Quality of life and sexual changes after double transobturator tension-free approach to treat severe cystocele. Eur J Obstet Gynecol Reprod Biol. 2010;151:106–109.
    1. Laganà AS, La Rosa VL, Palumbo MA, et al. The impact of stress urinary incontinence on sexual function and quality of life. Gazz Medica Ital. 2018;177:415–416.
    1. Vitale SG, La Rosa VL, Rapisarda AMC, et al. Sexual life in women with stress urinary incontinence. Oman Med J. 2017;32:174–175.
    1. Yip SK, Chan A, Pang S, et al. The impact of urodynamic stress incontinence and detrusor overactivity on marital relationship and sexual function. Am J Obstet Gynecol. 2003;188:1244–1248.
    1. Zahariou A, Karamouti M, Tyligada E, et al. Sexual function in women with overactive bladder. Female Pelvic Med Reconstr Surg. 2010;16:31–36.
    1. Sen I, Onaran M, Tan MO, et al. Evaluation of sexual function in women with overactive bladder syndrome. Urol Int. 2007;78:112–115.
    1. Del Rosso A, Pace G, Di Pierro ED, et al. Impact of Overactive Bladder on Sexual Function in Women. Urol J. 2011;78:200–202.
    1. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000;26:191–208.
    1. Cozzolino M, Magro-Malosso ER, Tofani L, et al. Evaluation of sexual function in women with deep infiltrating endometriosis. Sex Reprod Healthc. 2018;16:6–9.
    1. Zomkowski K, Toryi AM, Sacomori C, et al. Sexual function and quality of life in gynecological cancer pre- and post-short-term brachytherapy: a prospective study. Arch Gynecol Obstet. 2016;294:833–840.
    1. Caruso S, Cianci S, Vitale SG, et al. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy. Eur J Contracept Reprod Health Care. 2018;23:24–31.
    1. Mollaioli D, Lin L-T, Shah M, et al. Multidisciplinary management of sexual quality of life among menopausal women with urogynecological complains. Ital J Gynaecol Obstet. 2018;30:15–20.
    1. La Rosa VL, Sapia F, Salvaggio C, et al. Quality of life and sexual function in women with genitourinary syndrome of menopause (GSM): effectiveness of local therapy with ultralow-concentration estriol vaginal gel. Ital J Gynaecol Obstet. 2018;30:7–13.
    1. Caruso S, Cianci S, Vitale SG, et al. Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse. Menopause. 2017;24:900–907.
    1. Laganà AS, Vitale SG, Stojanovska L, et al. Preliminary results of a singlearm pilot study to assess the safety and efficacy of visnadine, prenylflavonoids and bovine colostrum in postmenopausal sexually active women affected by vulvovaginal atrophy. Maturitas. 2018;109:78–80.
    1. Klutke CG, Burgio KL, Wyman JF, et al. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication. J Urol. 2009;181:2599–2607.
    1. Bartley JM, Blum ES, Sirls LT, et al. Understanding clinic options for overactive bladder. Curr Urol Rep. 2013;14:541–548.
    1. Olivera CK, Meriwether K, El-Nashar S, et al. Nonantimuscarinic treatment for overactive bladder: a systematic review. Am J Obstet Gynecol. 2016;215:34–57.
    1. Sears CLG, Lewis C, Noel K, et al. Overactive bladder medication adherence when medication is free to patients. J Urol. 2010;183:1077–1081.
    1. Kurpad R, Kennelly MJ. The evaluation and management of refractory neurogenic overactive bladder. Curr Urol Rep. 2014;15:444.
    1. Laviana A, Jellison F, Kim J-H. Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome. Neurosurg Clin N Am. 2014;25:33–46.
    1. Fossberg E, Sørensen S, Ruutu M, et al. Maximal electrical stimulation in the treatment of unstable detrusor and urge incontinence. Eur Urol. 1990;18:120–123.
    1. Yamanishi T, Yasuda K, Sakakibara R, et al. Randomized, double-blind study of electrical stimulation for urinary incontinence due to detrusor overactivity. Urology. 2000;55:353–357.
    1. Monga AK, Tracey MR, Subbaroyan J. A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction. Int Urogynecol J. 2012;23:993–1005.
    1. Schmidt AP, Sanches PRS, Silva DP, et al. A new pelvic muscle trainer for the treatment of urinary incontinence. Int J Gynaecol Obstet. 2009;105:218–222.
    1. Berghmans LC, Hendriks HJ, De Bie RA, et al. Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials. BJU Int. 2000;85:254–263.
    1. Alves PGJM, Nunes FR, Guirro ECO. Comparison between two different neuromuscular electrical stimulation protocols for the treatment of female stress urinary incontinence: a randomized controlled trial. Rev Bras Fisioter. 2011;15:393–398.
    1. Castro RA, Arruda RM, Zanetti MRD, et al. Single-blind, randomized, controlled trial of pelvic floor muscle training, electrical stimulation, vaginal cones, and no active treatment in the management of stress urinary incontinence. Clinics (Sao Paulo) 2008;63:465–472.
    1. Seo JT, Choe JH, Lee WS, et al. Efficacy of functional electrical stimulation-biofeedback with sexual cognitive-behavioral therapy as treatment of vaginismus. Urology. 2005;66:77–81.
    1. Rosenbaum TY. Physiotherapy treatment of sexual pain disorders. J Sex Marital Ther. 2005;31:329–340.
    1. Amaro JL, Oliveira Gameiro MO, Padovani CR. Treatment of urinary stress incontinence by intravaginal electrical stimulation and pelvic floor physiotherapy. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14:204–208. discussion 208.
    1. Giuseppe PG, Pace G, Vicentini C. Sexual function in women with urinary incontinence treated by pelvic floor transvaginal electrical stimulation. J Sex Med. 2007;4:702–707.
    1. Rivalta M, Sighinolfi MC, De Stefani S, et al. Biofeedback, electrical stimulation, pelvic floor muscle exercises, and vaginal cones: a combined rehabilitative approach for sexual dysfunction associated with urinary incontinence. J Sex Med. 2009;6:1674–1677.
    1. Rivalta M, Sighinolfi MC, Micali S, De Stefani S, Bianchi G. Sexual function and quality of life in women with urinary incontinence treated by a complete pelvic floor rehabilitation program (biofeedback, functional electrical stimulation, pelvic floor muscles exercises, and vaginal cones) J Sex Med. 2010;7:1200–1208.
    1. Amaro JL, Gameiro MO, Padovani CR. Effect of intravaginal electrical stimulation on pelvic floor muscle strength. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16:355–358.
    1. Tanagho EA, Schmidt RA. Electrical stimulation in the clinical management of the neurogenic bladder. J Urol. 1988;140:1331–1339.
    1. Bartley J, Gilleran J, Peters K. Neuromodulation for overactive bladder. Nat Rev Urol. 2013;10:513–521.
    1. Sukhu T, Kennelly MJ, Kurpad R. Sacral neuromodulation in overactive bladder: a review and current perspectives. Res Reports Urol. 2016;8:193–199.
    1. Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11–18.
    1. Tadic SD, Griffiths D, Schaefer W, et al. Brain activity underlying impaired continence control in older women with overactive bladder. Neurourol Urodyn. 2012;31:652–658.
    1. Latini JM, Alipour M, Kreder KJ. Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence. Urology. 2006;67:550–553. discussion 553-554.
    1. Hassouna MM, Siegel SW, Nÿeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000;163:1849–1854.
    1. Schmidt RA, Jonas U, Oleson KA, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol. 1999;162:352–357.
    1. Lombardi G, Finazzi Agrò E, Del Popolo G. Sacral neuromodulation and female sexuality. Int Urogynecol J. 2015;26:1751–1757.
    1. Khunda A, McCormick C, Ballard P. Sacral neuromodulation and sexual function: a systematic review and meta-analysis of the literature. Int Urogynecol J. 2019;30:339–352.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner